Ipilimumab Combined With a Stereotactic Radiosurgery in Melanoma Patients With Brain Metastases

Model scores of the 29,894 trials active now.

Model score 30% for any early termination, 12% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2015-12-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: brainmriipilimumabmelanomametastatic
  Phrases that lowered it: hcvsubjectspatientssafetykg
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Disease area, cancer: Yes (raises risk) · Disease area
• Drug's FAERS reports with a death: 26.3% (raises risk) · Drug's FDA history
• Phase: 2 (raises risk) · Design
• Design: single group (raises risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Disease area, neurology: Yes (raises risk) · Disease area
• Minimum age: 18 (raises risk) · Who can join
• Trials the sponsor started in the prior 2 years: 19 (lowers risk) · Sponsor's track record
• Collaborators: 1 (raises risk) · Design
• Maximum age: not given (raises risk) · Who can join
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Disease area, dermatology: Yes (raises risk) · Disease area
• Number of arms: 1 (raises risk) · Design
• Drug's FAERS reports before start: 1579 (raises risk) · Drug's FDA history
• Sponsor's past trials: 16 (lowers risk) · Sponsor's track record

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• SRS (Stereotactic Radiosurgery) Plus Ipilimumab NCT01950195 · started 2013 · scored riskier than 87% of active trials terminated
• An Investigational Immuno-therapy Study to Evaluate Safety and Effectiveness in Patients With Melanoma That Has Spread to the Brain, Treated With Nivolumab in Combination With Ipilimumab, Followed by Nivolumab by Itself NCT02320058 · started 2015 · scored riskier than 74% of active trials completed
• Ipilimumab and Stereotactic Body Radiation Therapy (SBRT) in Advanced Solid Tumors NCT02239900 · started 2014 · scored riskier than 81% of active trials completed
• Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma NCT01703507 · started 2012 · scored riskier than 91% of active trials completed
• GEM STUDY: Radiation And Yervoy in Patients With Melanoma and Brain Metastases NCT02115139 · started 2014 · scored riskier than 67% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.